No Data
No Data
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The
Following a 59% Decline Over Last Year, Recent Gains May Please Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners
Key Insights Institutions' substantial holdings in Vir Biotechnology implies that they have significant influence over the company's share price The top 6 shareholders own 55% of the company
Form 144 | Vir Biotechnology(VIR.US) Director Proposes to Sell 240.84K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Vir Biotechnology(VIR.US)$ Director SHARP PHILLIP A intends to sell 25,897 shares of its common stock on Jul 10, with a total market value of approximately $240.84K.
Vir Biotechnology Says FDA Cleared IND Application for Chronic Hepatitis D Drug Combination
Vir Biotechnology (VIR) said Wednesday the US Food and Drug Administration has cleared its investigational new drug application and granted a fast-track designation for the combination of its drug can
Express News | Vir Biotechnology Inc - Complete 24-Week Treatment Data Expected Q4
Express News | Vir Biotechnology Receives FDA Ind Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection